All information on this page is subject to MCDSA’s disclaimer.
Among common CBD benefits, natural pain relief tops the list for many. Evidence suggests that cannabinoids may prove useful in pain modulation by inhibiting neuronal transmission in pain pathways. A 2012 study published in the Journal of Experimental Medicine found that CBD significantly suppressed chronic inflammatory and neuropathic pain in rodents without causing analgesic tolerance. Researchers suggest that CBD and other non-psychoactive components of cannabis may represent a novel class of therapeutic agents for the treatment of chronic pain.
Research shows that CBD benefits include producing antipsychotic effects. It appears to have a pharmacological profile similar to that of atypical antipsychotic drugs as seen using behavioral and neurochemical techniques in animal studies. Additionally, studies show that CBD prevents human experimental psychosis and is effective in open case reports and clinical trials in patients with schizophrenia, with a remarkable safety profile.
Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Cannabidiol has shown to reduce anxiety in patients with social anxiety disorder and researchers suggest that it may also be effective for panic disorder, obsessive compulsive disorder, social anxiety disorder and post-traumatic stress disorder.
Several scientific reports demonstrate that CBD benefits include possessing antiproliferative, pro-apoptotic effects that inhibit cancer cell migration, adhesion and invasion. A 2006 study published in the Journal of Pharmacology and Experimental Therapeutics found for the first time that CBD potently and selectively inhibited the growth of different breast tumor cell lines and exhibited significantly less potency in non-cancer cells. Data also suggests that CBD can be used to inhibit the invasion of lung and colon cancer, plus it possesses anti-tumor properties in gliomas and has been used to treat leukemia.
Cannabis has been used for centuries for the suppression of nausea and vomiting. Research has revealed that among more than 80 cannabinoid compounds found in marijuana, both the intoxicant THC and the non-intoxicant CBD helps to get rid of nausea and vomiting in animal studies. A 2012 study found that CBD benefits including possessing anti-nausea and antiemetic effects when it was administered to rats.
A 2014 survey conducted by researchers at Stanford University was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child’s seizures. Nineteen responses met the inclusion criteria for the study: a diagnosis of epilepsy and current use of CBD-enriched cannabis. The average number of anti-epileptic drugs tried before using CBD cannabis was 12. Sixteen (84 percent) of the 19 parents reported a reduction in their child’s seizure frequency while taking CBD cannabis. Of these, two (11 percent) reported complete seizure freedom, eight (42 percent) reported a greater than 80 percent reduction in seizure frequency, and six (32 percent) reported a 25–60 percent seizure reduction. Other beneficial effects included increased alertness, better mood and improved sleep; while side effects included drowsiness and fatigue.
Later in 2014, researchers reported on preliminary results of a study involving children with treatment-resistant epilepsies in an expanded access “compassionate use program.” Patients received a purified 98 percent oil-based CBD extract called Epidiolex, which is made by GW Pharmaceuticals. After 3 months of treatment, 39 percent of the 23 patients had more than a 50 percent reduction in seizures, with a 32 percent median reduction. These preliminary results support the animal studies and survey reports that CBD may be a promising treatment for treatment-resistant epilepsy and it is generally well-tolerated in doses up to 25 milligrams per kilogram of body weight.
A 2006 study found that CBD treatment significantly reduced the incidence of diabetes in non-obese diabetic mice from an incidence of 86 percent in non-treated mice to an incidence of 30 percent in CBD-treated mice. CBD benefits also showed a significant reduction of plasma levels of pro-inflammatory cytokines. A histological examination of the pancreatic islets of the CBD-treated mice revealed significantly reduced insulitis.
A 2013 study published in the British Journal of Clinical Pharmacology reports that CBD protects against the vascular damage caused by a high glucose environment, inflammation or the induction of type 2 diabetes in animal models.